Medpacto Announces 15.8 mOS in Colorectal Cancer Clinical Trial at ASCO

Medpacto Announces 15.8 mOS in Colorectal Cancer Clinical Trial at ASCO… 2x results compared to standard therapy. For the first time, the median overall survival (mOS) of Vactosertib and Keytruda combination therapy was disclosed in phase 1b and 2a trials. Medpacto (CEO Seong-Jin Kim) presented the results of clinical trials for colorectal cancer and multiple myeloma at the annual meeting of the American Society of Clinical Oncology (ASCO). Medpacto disclosed for the first time that the median overall survival (mOS) was 15.8 months as a result of an interim analysis of phase 1b and 2a clinica..........

원문링크 : Medpacto Announces 15.8 mOS in Colorectal Cancer Clinical Trial at ASCO